Sickle Cell Disease clinical trials near you

8 shown of 138

8 shown of 138 clinical trials.

1. RecruitingPhase 4InterventionalNCT07177300

   Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

   Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)

   The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA. In this research study, the investigators hope to learn more about how to improve the dosing and monitoring of hydroxyurea and learn more about the long-term effects of hydroxyurea over time. Hydroxyurea is usually dosed based only on your weight. Our study will use a new way to select a starting dose that is based on how each patient absorbs hydroxyurea.

   Sites

   1

   Target

   50

   Study sites

   Cincinnati, US

   Sponsor: Children's Hospital Medical Center, Cincinnati

   View on ClinicalTrials.gov(opens in a new tab) Express interest
2. RecruitingPhase 2InterventionalNCT07282210

   Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

   Sickle Cell Disease, Sickle Cell Anaemia, Sickle Cell Anemia

   SIL-8301 (senicapoc) is being developed for the chronic treatment of patients with sickle cell disease in both adults and children. The purpose of this study is to compare the effects of senicapoc to placebo in patients with sickle cell disease that have had fewer than 2 acute sickle-related painful crises per year over the preceding 2 years, and have a predominantly hemolytic phenotype, defined as presence or history of at least one hemolytic complication and a baseline Hb of 9 g/dL or less, despite receiving hydroxyurea (an oral drug used for treatment of sickle cell disease) as standard of care. Participants will take senicapoc or matching placebo daily and continue on hydroxyurea as prescribed for up to 24 weeks.

   Sites

   4

   Target

   105

   Study sites

   Toronto, CA +3 more

   Sponsor: Biossil Inc.

   View on ClinicalTrials.gov(opens in a new tab) Express interest
3. RecruitingPhase 3InterventionalNCT06818266

   Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

   Sickle Cell Disease, Acute Chest Syndrome

   The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients with sickle cell disease (SCD) during acute chest syndrome (ACS).

   Sites

   1

   Target

   130

   Study sites

   Paris, FR

   Sponsor: Assistance Publique - Hôpitaux de Paris

   View on ClinicalTrials.gov(opens in a new tab) Express interest
4. RecruitingPhase 1, Phase 2InterventionalNCT07432867

   Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.

   Sickle Cell Disease

   The purpose of this study is to evaluate the Safety and Efficacy of DREAM01, a gene therapy for Sickle Cell Disease (SCD). The therapy consists of transplanting autologous CD34+ cells transduced ex vivo with a bifunctional lentiviral vector expressing βAS3m-globin and an anti-βS miRNA. It aims to reduce or eliminate vaso-occlusive events and long-term organ damage in severe SCD patients lacking a Human Leukocyte Antigen (HLA) identical sibling donor.

   Sites

   1

   Target

   15

   Study sites

   Paris, FR

   Sponsor: Assistance Publique - Hôpitaux de Paris

   View on ClinicalTrials.gov(opens in a new tab) Express interest
5. RecruitingInterventionalNCT05383911

   Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)

   Sickle Cell Disease

   This study will evaluate the acceptability, feasibility, and preliminary efficacy of a shared decision making intervention for adolescents and young adults (AYAs) with sickle cell disease (SCD). 60 AYAs with SCD ages 15-25 and their caregivers and 8 SCD providers will participate in the pilot pragmatic trial. AYAs, caregivers, and providers will be recruited from Nemours Children's Hospital, Delaware (NCH-DE), Nemours Children's Hospital in Orlando, FL (NCH-ORL), and Nemours Children's Health at Wolfson Children's Hospital in Jacksonville, FL (NCH-JAX). NCH-DE participants (n=30) will receive the SDM intervention including a virtual reality patient health education component, whereas NCH-ORL and NCH-JAX participants (n=30) will receive the SDM intervention with standard patient education materials (print, video). SCD providers will be trained to use the toolkit components and will introduce decision aids during an outpatient clinic visit for AYAs who are candidates for one or more disease-modifying therapies.

   Sites

   1

   Target

   68

   Study sites

   Wilmington, US

   Sponsor: Nemours Children's Clinic

   View on ClinicalTrials.gov(opens in a new tab) Express interest
6. RecruitingPhase 1InterventionalNCT07566494

   Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

   Sickle Cell Disease, Hemolytic Anemia

   Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen. Research has shown that curcumin, a natural compound found in turmeric, can improve the health of red blood cells in people with SCD. But the body cannot absorb curcumin well when it is taken by mouth. Researchers want to know if a skin gel (VAS-101) can help the body better absorb curcumin. VAS-101 contains curcumin, which comes from turmeric. Objective: To test VAS-101 in people with stable SCD. Eligibility: People aged 18 to 70 years with stable SCD. Design: People who want to join the study will be screened with physical exam with blood tests to see if they are eligible. If they qualify, they can enroll in the study. Participants will have up to 15 clinic visits over about 14 weeks. Some may need to stay overnight in the hospital for up to 2 days to make it easier to collect blood samples after the gel is applied. For 6 weeks, a special gel called VAS-101 will be put on the forearms in the clinic two times a week. Staff will rub the gel into the skin for at least 30 seconds using a soft toothbrush. The area stays uncovered for at least 10 minutes, then is covered with a bandage or sleeve. After 24 hours, the dressing can be removed and the skin can be washed. Some visits will include blood tests and other exams. On three visits, a test called near infrared spectroscopy (NIRS) will be done. For this test, probes are placed on the skin to measure blood flow, oxygen levels, and the makeup of skin and muscle. A blood pressure cuff is used to squeeze the arm for up to 5 minutes. The last clinic visit will happen about 4 weeks after the final gel application....

   Sites

   1

   Target

   25

   Study sites

   Bethesda, US

   Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

   View on ClinicalTrials.gov(opens in a new tab) Express interest
7. RecruitingInterventionalNCT07610239

   Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening

   Sickle Cell Disease

   A cluster randomized trial (CRT) of the novel sickle cell disease (SCD), M-health based SCD Information Management and Communication system SIMCS vs routine new born screening strategy in health care centres in Uganda to evaluate impact on access screening, coordination of care and clinical outcomes

   Sites

   1

   Target

   24,000

   Study sites

   Jinja, UG

   Sponsor: Makerere University

   View on ClinicalTrials.gov(opens in a new tab) Express interest
8. RecruitingInterventionalNCT06619197

   Exploratory Study on Global Reflexology in Sickle Cell Disease

   Sickle Cell Disease (SCD)

   Sickle cell disease (or sickle cell anemia) is the most common genetic disease in France with 586 children screened in 2019. This chronic disease is characterized by the presence of abnormal Hemoglobin (Hb) S and a deformation of the red blood cells which take the elongated shape of a sickle and become more rigid and more fragile. Sickle cell disease manifests itself among other things by very painful vaso-occlusive crises (VOC) and for some chronic pain. Their management is an emergency and often requires hospitalization. Despite analgesic treatment, some patients have persistent pain. In 2013, a childcare assistant trained in Canadian global reflexology EMC offered reflexology sessions to 12 sickle cell patients. She observed a relief in all patients with a decrease in the pain score in 8 of them. These sessions seem to show us a double interest: the reduction of the child\'s pain and the emergence of a technique that can be used by paramedics in the context of their own role. The investgators hypothesize that global reflexology is an effective and acceptable complementary technique for pain management in addition to the usual analgesic management in sickle cell children under 18 years of age in CVO. In order to verify our hypothesis, the investigators propose to explore the practice of Canadian global reflexology as an innovative therapeutic option complementary to drug treatments in the hospital management of sickle cell children.

   Sites

   1

   Target

   30

   Study sites

   Bron, FR

   Sponsor: Hospices Civils de Lyon

   View on ClinicalTrials.gov(opens in a new tab) Express interest